Ferring Pharmaceuticals 的研究发现，粪便钙卫蛋白监测的靶向治疗方法可改善轻度至中度溃疡性结肠炎患者的预后。 Ferring Pharmaceuticals study finds treat-to-target approach with faecal calprotectin monitoring improves outcomes in mild-to-moderate ulcerative colitis patients.
费林制药公司宣布了OPTIMISE研究的结果,该研究评估了治疗到标 (T2T) 方法,使用便中calprotectin (FC) 监测对轻度至中度性结肠炎 (M2M UC) 患者进行监测. Ferring Pharmaceuticals announced findings from the OPTIMISE study, which assessed a treat-to-target (T2T) approach using faecal calprotectin (FC) monitoring for patients with mild-to-moderate ulcerative colitis (M2M UC). 研究表明,T2T显著改善了结果,患者的临床和内镜缓解率比传统的基于症状的方法高17- 22%. The study indicated that T2T significantly improved outcomes, with patients achieving 17-22% higher rates of clinical and endoscopic remission compared to traditional symptom-based methods. 这项研究支持T2T管理炎性肠道疾病战略。 This research supports the T2T strategy for managing inflammatory bowel disease.